RLMD - Relmada Therapeutics Inc

https://www.relmada.com

Momentum: Bearish

Recent News

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

GlobeNewswire • 1 month, 2 weeks ago • score: 0.27

CORAL GABLES, Fla., July 31, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York.

52W High

$3.98

52W Low

$0.24

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.74

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.54

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

3.43

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

18.85%

Institutions (25–75% balanced)

34.35%

Shares Outstanding

33,191,600

Float

23,007,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.20

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.75%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.3149

0.3161

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025